Hikma Pharmaceuticals (LON:HIK) Upgraded by Berenberg Bank to “Buy”

Berenberg Bank upgraded shares of Hikma Pharmaceuticals (LON:HIK) to a buy rating in a report released on Monday morning, Digital Look reports. They currently have GBX 2,400 ($31.56) price objective on the stock, up from their prior price objective of GBX 2,100 ($27.61).

A number of other brokerages also recently commented on HIK. Deutsche Bank Aktiengesellschaft reissued a buy rating and set a GBX 2,750 ($36.16) price objective on shares of Hikma Pharmaceuticals in a research report on Tuesday, June 18th. Barclays restated an equal weight rating and issued a GBX 2,000 ($26.30) price target on shares of Hikma Pharmaceuticals in a research note on Tuesday, May 7th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus price target of GBX 2,325 ($30.57).

Hikma Pharmaceuticals Price Performance

Shares of HIK opened at GBX 1,998 ($26.27) on Monday. The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.48. Hikma Pharmaceuticals has a fifty-two week low of GBX 1,711 ($22.50) and a fifty-two week high of GBX 2,193 ($28.84). The company has a market cap of £4.43 billion, a P/E ratio of 3,073.85, a PEG ratio of 2.38 and a beta of 0.40. The firm’s 50 day moving average price is GBX 1,918.13 and its 200 day moving average price is GBX 1,921.

Hikma Pharmaceuticals Cuts Dividend

The firm also recently declared a dividend, which will be paid on Friday, September 20th. Investors of record on Thursday, August 15th will be given a $0.32 dividend. The ex-dividend date is Thursday, August 15th. This represents a yield of 1.37%. Hikma Pharmaceuticals’s dividend payout ratio (DPR) is 9,538.46%.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.